Drug Shows Some Promise for PTCL Sufferers
Peripheral T-cell lymphoma (PTCL) attacks only about ten percent of people diagnosed with non-Hodgkin's lymphoma every year but it’s a very deadly form of lymphoma and one of the most difficult to treat. Furthermore, there are currently no FDA-approved treatments for PTCL.
A recent clinical trial carried out by Allos Therapeutics for the experimental drug pralatrexate showed that of the 115 PTCL patients, 27% responded to the drug while 11% reached full remission. Patients responded to the drug for an average of 9.4 months, substantially longer than anyone expected.
The good results surprised Allos. They intend to seek regulatory approval of pralatrexate, also known as PDX, later this year. The FDA has granted the drug orphan status, and Allos is testing it against other forms of cancer.
Pralatrexate works by disguising itself as a folic acid which a cancerous tumor readily absorbs. Once inside, the drug attacks the tumor.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
